Kinase News and Research

RSS

Protein can nurture or devastate brain cells, depending on its 'friends,' UT Southwestern researchers find

Researchers at UT Southwestern Medical Center have uncovered new insights into the "Dr. Jekyll and Mr. Hyde" nature of a protein that stimulates stem-cell maturation in the brain but, paradoxically, can also lead to nerve-cell damage.

11 Nov 2008

Alteration of a gene causes neuroblastoma

Olivier Delattre's team (Inserm Unit 830 "Genetics and Biology of Cancer") of the Institut Curie reveal in an article in the 16 October issue of Nature that alteration of the ALK gene is closely associated with the most frequent solid extracerebral tumor in children-neuroblastoma. By studying the familial forms of this tumor, the researchers also conclude that ALK is a gene that predisposes to neuroblastoma.

7 Nov 2008

Apelin hormone shows promise as target for managing insulin resistance and type 2 diabetes

By injecting a hormone produced by fat and other tissues into mice, researchers report in the November Cell Metabolism that they significantly lowered blood sugar levels in normal and obese mice.

5 Nov 2008

YM Biosciences reports on early trials of nimotuzumab in brain metastases and high-grade glioma

YM BioSciences Inc. has announced data from two clinical trials of nimotuzumab, its humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR). Preliminary results from the two trials which are evaluating nimotuzumab in combination with radiation therapy for the treatment of brain metastases and high-grade gliomas, conducted by YM's licensor, were presented at the 2008 EORTC-NCI-AACR annual meeting recently held in Geneva, Switzerland.

3 Nov 2008

Gene study sheds new light on lung cancer

A multi-institution team, funded by the National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH), today reported results of the largest effort to date to chart the genetic changes involved in the most common form of lung cancer, lung adenocarcinoma. The findings should help pave the way for more individualized approaches for detecting and treating the nation's leading cause of cancer deaths.

22 Oct 2008

Getting to grips with the complexity of disease proteins

Drug molecules seldom act simply on one protein but on protein complexes and networks. A deeper understanding of these 'cooperative assemblies' should lead to better targeting of drugs.

20 Oct 2008

Resveratrol shows promise for treating human alcoholic fatty liver disease

The accumulation of fat in the liver as a result of chronic alcohol consumption could be prevented by consuming resveratrol, according to a new study with mice. The research found that resveratrol reduced the amount of fat produced in the liver of mice fed alcohol and, at the same time, increased the rate at which fat within the liver is broken down.

14 Oct 2008

Kinaxo partners with Boehringer Ingelheim

Kinaxo Biotechnologies GmbH announced today that it has entered into a two-year collaboration with Boehringer Ingelheim. Under the agreement Kinaxo will apply its new platform technologies to studies on drug mode of action and target identification. Financial details of the agreement were not disclosed.

13 Oct 2008

Exelixis files investigational new drug application for anticancer compound

Exelixis, Inc. announced today that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration for XL888, a novel anticancer compound. XL888 is an orally available small molecule inhibitor of HSP90, which is a chaperone protein that promotes the activity and stability of a range of key regulatory proteins, including kinases.

2 Oct 2008

Cancer Research UK and Astex Therapeutics join forces to develop new anti-cancer treatment

Cancer Research UK, Cancer Research Technology (CRT) - the charity's development and commercialisation arm - and Astex Therapeutics Limited announced today that they have agreed to take into development a potential new anti-cancer treatment.

30 Sep 2008

S*BIO initiates trials of oral JAK2 inhibitor for hematological malignancies

S*BIO Pte Ltd today announced the initiation of multi-center Phase I clinical trials of SB1518, a potent and orally-active JAK2 inhibitor, in patients with leukemia and certain types of lymphoma.

17 Sep 2008

Discovery of promising new chemotherapy target for a deadly form of leukemia

Cancer researchers at the Stanford University School of Medicine have discovered a promising new chemotherapy target for a deadly form of leukemia. Their discovery hinges on a novel "double agent" role for a molecular signal that regulates cell growth.

17 Sep 2008

Significant benefits in non-small-cell lung cancer from customizing erlotinib treatment

Lung cancer patients whose tumors carry specific genetic mutations can achieve significantly longer survival when treated with targeted therapies such as erlotinib, Spanish researchers report.

15 Sep 2008

Neuroscientists discover a critical early step of memory formation

Researchers at the Johns Hopkins University School of Medicine report in the July issue of Neuron how nerve cells in the brain ensure that Arc, a protein critical for memory formation, is made instantly after nerve stimulation. Paradoxically, its manufacture involves two other proteins - including one linked to mental retardation - that typically prevent proteins from being made.

14 Sep 2008

The underdevelopment of a specific brain region may cause schizophrenia

The underdevelopment of a specific region in the brain may lead to schizophrenia in individuals. According to research published today in BioMed Central's open access journal Molecular Brain, dentate gyrus, which is located in the hippocampus in the brain and thought to be responsible for working memory and mood regulation, remained immature in an animal model of schizophrenia.

10 Sep 2008

GlaxoSmithKline and Cellzome announce major strategic alliance

Cellzome Inc. and GlaxoSmithKline have announced the signing of a worldwide strategic alliance to discover, develop and market novel kinase-targeted therapeutics to treat inflammatory diseases.

10 Sep 2008

Antisoma commences phase II trial of AS1411 in metastatic renal cell carcinoma

Cancer drug developer Antisoma plc today announced that it has started a phase II study of AS1411 in metastatic renal cell carcinoma (kidney cancer).

4 Sep 2008

New discovery on growth factor - breakthrough for cancer research

A research team at the Ludwig Institute and Uppsala University has discovered an entirely new signal path for a growth factor that is of crucial importance for the survival and growth of cancer cells.

2 Sep 2008

Atomic bomb's effect results in adult-onset thyroid cancer

Radiation from the atomic bomb blasts in Hiroshima and Nagasaki, Japan, in 1945, likely rearranged chromosomes in some survivors who later developed papillary thyroid cancer as adults, according to Japanese researchers.

1 Sep 2008

Gleevec receives FDA priority review for gastrointestinal stromal tumors after surgery

Novartis has announced that Gleevec (imatinib mesylate) tablets, (known as Glivec (imatinib) outside the US, Canada and Israel), has been granted priority review status by the US Food and Drug Administration (FDA) as the first therapy to be reviewed for use after surgery in kit-positive gastrointestinal stromal tumors (GIST).

27 Aug 2008